drugset / Trial / NCT02307162

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

NCT02307162

Phase 1 Completed 112 enrolled Verona Pharma, Inc.
RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of the study is to assess the safety of single doses and multiple doses of a new formulation of RPL554 in healthy subjects and subjects with chronic obstructive pulmonary disorder.

Timeline

Start
2014-12
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensifentrine Unknown 1.5 mg/ml Inhaled